IMTX
HEALTHCAREImmatics N.V
$11.51+0.56 (+5.11%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IMTX Today?
No stock-specific AI insight has been generated for IMTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.15$12.41
$11.51
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-1.89
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume748K
Avg Volume (10D)—
Shares Outstanding134.1M
IMTX News
20 articles- ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales GrowthYahoo Finance·May 7, 2026
- Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpYahoo Finance·May 7, 2026
- RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/YYahoo Finance·May 7, 2026
- Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- All You Need to Know About Immatics (IMTX) Rating Upgrade to BuyYahoo Finance·May 6, 2026
- Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue EstimatesYahoo Finance·May 4, 2026
- Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual MeetingYahoo Finance·Apr 21, 2026
- PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic NephroblastomaGlobeNewswire Inc.·Apr 17, 2026
- Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch UpsideYahoo Finance·Mar 15, 2026
- Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug CandidateYahoo Finance·Mar 13, 2026
- Immatics: Q4 Earnings SnapshotYahoo Finance·Mar 5, 2026
- Immatics Announces Full Year 2025 Financial Results and Business UpdateYahoo Finance·Mar 5, 2026
- Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Feb 26, 2026
- Institutional investors own a significant stake of 38% in Immatics N.V. (NASDAQ:IMTX)Yahoo Finance·Jan 15, 2026
- Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA SaysYahoo Finance·Jan 6, 2026
- Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 CongressYahoo Finance·Dec 11, 2025
- Immatics (NasdaqCM:IMTX) Valuation Check After Follow-On Share Offering AnnouncementYahoo Finance·Dec 6, 2025
- Immatics Announces $125 Million Underwritten OfferingYahoo Finance·Dec 5, 2025
- Company News for Nov 18, 2025Yahoo Finance·Nov 18, 2025
- Should Immatics' (IMTX) New Clinical Data on IMA402 and IMA401 Prompt Fresh Investor Attention?Yahoo Finance·Nov 18, 2025
All 20 articles loaded
Price Data
Open$10.92
Previous Close$10.95
Day High$11.22
Day Low$10.57
52 Week High$12.41
52 Week Low$4.15
52-Week Range
$4.15$12.41
$11.51
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-1.89
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume748K
Avg Volume (10D)—
Shares Outstanding134.1M
About Immatics N.V
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—